Literature DB >> 10845918

Synergistic effects of in vivo depletion of Ly-49A and Ly-49G2 natural killer cell subsets in the rejection of H2(b) bone marrow cell allografts.

A Raziuddin1, M Bennett, R Winkler-Pickett, J R Ortaldo, D L Longo, W J Murphy.   

Abstract

Subsets of murine natural killer (NK) cells exist that express the Ly-49 family of molecules that recognize different major histocompatibility complex (MHC) determinants. Bone marrow transplantation studies were performed to examine the in vivo functions of 2 of these subsets. Subsets of Ly-49A and Ly-49G2 NK share specificity for the same MHC class 1 ligand, D(d), binding of which results in an inhibitory signal to the NK cell but allows them to lyse H2(b) targets in vitro. We therefore examined the ability of these subsets to reject H2(b) bone marrow cell allografts in lethally irradiated mice. Surprisingly, depletion of Ly-49A(+) NK cells in BALB/c or B10.D2 mice (both H2(d)) had no effect on the rejection of H2(b) BMC. However, Ly-49A depletion did partially abrogate the ability of B10.BR (H2(k)) mice to reject H2(b) allografts. Although depletion of either Ly-49A(+) or Ly-49G2(+) NK cells alone had no effect on the ability of B10.D2 mice to reject H2(b) BMC, depletion of both subsets dramatically and synergistically abrogated rejection. Studies with various B10 congenic mice and their F(1) hybrids indicate that this synergy between Ly49A and Ly4G2 depletion occurs in every instance. Thus, Ly-49A(+) NK cells appear to play a role in the rejection H2(b) bone marrow allografts, but, in most strains of mice studied, Ly-49G2(+) NK cells must also be eliminated. The putative roles of these NK cell subsets in clinical transplantation remains to be elucidated. (Blood. 2000;95:3840-3844)

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10845918

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  7 in total

1.  Mouse NK cell-mediated rejection of bone marrow allografts exhibits patterns consistent with Ly49 subset licensing.

Authors:  Kai Sun; Maite Alvarez; Erik Ames; Isabel Barao; Mingyi Chen; Dan L Longo; Doug Redelman; William J Murphy
Journal:  Blood       Date:  2011-12-19       Impact factor: 22.113

2.  Cytomegalovirus immunoevasin reveals the physiological role of "missing self" recognition in natural killer cell dependent virus control in vivo.

Authors:  Marina Babić; Michal Pyzik; Biljana Zafirova; Maja Mitrović; Višnja Butorac; Lewis L Lanier; Astrid Krmpotić; Silvia M Vidal; Stipan Jonjić
Journal:  J Exp Med       Date:  2010-11-15       Impact factor: 14.307

3.  Mouse host unlicensed NK cells promote donor allogeneic bone marrow engraftment.

Authors:  Maite Alvarez; Kai Sun; William J Murphy
Journal:  Blood       Date:  2016-01-06       Impact factor: 22.113

4.  Increased antitumor effects using IL-2 with anti-TGF-β reveals competition between mouse NK and CD8 T cells.

Authors:  Maite Alvarez; Myriam N Bouchlaka; Gail D Sckisel; Can M Sungur; Mingyi Chen; William J Murphy
Journal:  J Immunol       Date:  2014-07-07       Impact factor: 5.422

5.  Contrasting effects of anti-Ly49A due to MHC class I cis binding on NK cell-mediated allogeneic bone marrow cell resistance.

Authors:  Maite Alvarez; Can M Sungur; Erik Ames; Stephen K Anderson; Claire Pomeroy; William J Murphy
Journal:  J Immunol       Date:  2013-06-10       Impact factor: 5.422

6.  Natural killer cell education in mice with single or multiple major histocompatibility complex class I molecules.

Authors:  Sofia Johansson; Maria Johansson; Eleftheria Rosmaraki; Gustaf Vahlne; Ramit Mehr; Mali Salmon-Divon; François Lemonnier; Klas Kärre; Petter Höglund
Journal:  J Exp Med       Date:  2005-04-04       Impact factor: 14.307

7.  In vivo administration of a JAK3 inhibitor to chronically siv infected rhesus macaques leads to NK cell depletion associated with transient modest increase in viral loads.

Authors:  Yoshiaki Takahashi; Ann E Mayne; Ladawan Khowawisetsut; Kovit Pattanapanyasat; Dawn Little; Francois Villinger; Aftab A Ansari
Journal:  PLoS One       Date:  2013-07-26       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.